AgResearch New Zealand Limited, Animal Health Division, Hopkirk, Research Institute, Grasslands Research Centre, Palmerston North, 4442, New Zealand.
Vaccine. 2012 Nov 26;30(50):7321-6. doi: 10.1016/j.vaccine.2012.08.076. Epub 2012 Sep 11.
Cattle may act as hosts for the transmission of the cestode parasite Echinococcus granulosus and play a role in transmission of the parasite leading to human cystic echinococcosis (CE). The recombinant EG95 vaccine has been shown to be able to protect cattle and other intermediate host species against CE. Ideally the immunisation of bovines against E. granulosus, using EG95 vaccine, should occur early in life so as to provide maximum protection against the establishment of hydatid cysts. Maternally derived antibody from vaccinated cows may provide some protection for the neonate, but may also interfere with the active response to vaccination. Experiments were undertaken to determine the optimal regime for protection of young cattle against CE. One group of pregnant cattle received 2 vaccinations of EG95 antigen+Quil A adjuvant two months and one month prior to calving. The control group of pregnant cattle were not vaccinated. Calves were either challenged with E. granulosus eggs at 4, 9, 13 or 17 weeks post-birth or were given their first vaccination at 8, 12 or 16 weeks post-birth. Sera obtained at regular intervals were tested by ELISA to assess the immunological response. All calves were experimentally challenged with E. granulosus eggs and subsequent necropsy confirmed the levels of protection. Maternal antibody was shown to protect calves to some extent for at least 17 weeks. Calves from vaccinated cows responded well serologically if the first vaccination was given at 8 or 12 weeks, but full protection against a challenge infection was achieved only if the first vaccination was delayed until 16 weeks after birth. Calves from non-vaccinated cattle also were not fully protected if the first vaccination was at 8 or 12 weeks, but were fully protected if the first vaccination was given when they were 16 weeks old. This suggests that immunological maturity is not acquired in calves until 4 or 5 months of age. No safety problems were observed following two vaccinations of 40 pregnant cows or 30 suckling calves.
牛可能作为带绦虫寄生虫细粒棘球绦虫的宿主,并在寄生虫传播导致人类包虫病(CE)方面发挥作用。重组 EG95 疫苗已被证明能够保护牛和其他中间宿主物种免受 CE 的侵害。理想情况下,使用 EG95 疫苗对牛进行免疫接种应在生命早期进行,以提供对包虫囊肿形成的最大保护。来自接种疫苗的奶牛的母源抗体可能为新生儿提供一些保护,但也可能干扰对疫苗接种的主动反应。进行了实验以确定保护小牛免受 CE 的最佳方案。一组怀孕的奶牛在分娩前两个月和一个月接受了两次 EG95 抗原+Quil A 佐剂的接种。对照组怀孕的奶牛未接种疫苗。小牛要么在出生后 4、9、13 或 17 周时接受细粒棘球蚴卵的挑战,要么在出生后 8、12 或 16 周时接受第一次接种。定期获得的血清通过 ELISA 测试以评估免疫反应。所有小牛均接受细粒棘球蚴卵的实验性挑战,随后的剖检证实了保护水平。母源抗体在至少 17 周内对小牛有一定程度的保护。如果在 8 或 12 周龄时进行第一次接种,接种疫苗的小牛在血清学上反应良好,但只有在出生后 16 周时进行第一次接种才能完全抵抗挑战感染。如果在 8 或 12 周龄时进行第一次接种,未接种疫苗的小牛也不能完全保护,但如果在 16 周龄时进行第一次接种,则可以完全保护。这表明小牛的免疫成熟直到 4 或 5 个月大时才获得。对 40 头怀孕奶牛或 30 头哺乳小牛进行两次接种后,未观察到安全性问题。